Blueprint Medicines Corp ASCO20 Conference Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Blueprint Medicines Conference Call. (Operator Instructions) I would now like to hand the conference over to your speaker today, Kristin Hodous of Blueprint Medicines. Please go ahead.
Thank you, operator. Good morning, everyone, and thank you for joining us today to review the updated clinical data for pralsetinib and RET fusion-positive lung and thyroid which we announced this morning as part of the American Society of Clinical Oncology 2020 Virtual Scientific Program. You can access the press release for the data as well slides that we'll be reviewing today by going to the Investors section of our website at www.blueprintmedicines.com.
With me today with prepared remarks are Jeff Albers, our Chief Executive Officer; Dr. Andy Boral, our Chief Medical Officer; and Christy Rossi, our Chief Commercial Officer.
Before we get started,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |